超声检出胎儿异常的妊娠中联合无细胞DNA筛查非整倍体及特定单基因病的检出率与残余风险
研究纳入116例孕12周起超声发现胎儿异常的单胎孕妇,行联合无细胞DNA(cfDNA)筛查非整倍体及25种显性单基因病,以外显子测序和核型分析为参考标准。联合cfDNA筛查较单纯非整倍体cfDNA额外检出率为22.9%,总体残余风险约2.0%,作者认为检查前需提供详细遗传咨询。
要点
- 超声胎儿异常孕妇中联合cfDNA筛查阳性率12.9%(15/116),阳性预测值86.7%(13/15)。
- 联合cfDNA较非整倍体cfDNA额外检出率22.9%,对遗传学异常的检出率37.1%(13/35)。
- 排除cfDNA可检出结果后,联合cfDNA的残余风险为2.0%(2/101)。
核心结论
- 超声胎儿异常时,联合cfDNA筛查非整倍体及25种单基因病较非整倍体cfDNA额外检出率达22.9%,总体残余风险约2.0%。
- 作者认为在这些妊娠中使用cfDNA分析前必须提供详细的遗传咨询。
研究设计与样本
- 研究纳入116例孕12周起超声发现胎儿异常的单胎孕妇,行联合cfDNA分析,以外显子测序和核型分析为参考标准。
- 将cfDNA分析结果与诊断性遗传检测进行比较。
主要发现
- cfDNA分析阳性率为15/116(12.9%),阳性预测值为13/15(86.7%)。
- 联合cfDNA筛查非整倍体及25种单基因病较非整倍体cfDNA在超声异常胎儿中的额外检出率为22.9%。
- 排除cfDNA可检出结果后,cfDNA分析非整倍体及致病/可能致病基因变异的残余风险为2/101(2.0%)。
- cfDNA分析对超声异常妊娠中遗传学异常的检出率为13/35(37.1%),与诊断性检测相比。
临床怎么用
- 作者认为在这些妊娠中使用cfDNA分析前必须提供详细的遗传咨询。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the additional detection rate (DR) and the residual risk (RR) of combined cell-free DNA (cfDNA) screening for aneuploidies (not including copy number variants) and 25 dominant single-gene disorders (SGD) in pregnancies with sonographic abnormalities. METHOD: One hundred sixteen singleton pregnant women with abnormal fetal ultrasounds from week 12 were included in the study. They underwent combined cfDNA analysis, while exome sequencing and karyotyping were performed as reference standards. The results of the cfDNA analysis were compared with diagnostic genetic tests. RESULTS: The positive rate of cfDNA analysis was 15/116 (12.9%), with a positive predictive value of 13/15 (86.7%). The incremental DR of combined cfDNA screening for aneuploidies and 25 SGD compared with cfDNA testing for aneuploidies in fetuses with sonographic anomalies was 22.9%. The RR of cfDNA analysis for aneuploidies and pathogenic/likely pathogenic gene variants, after excluding cfDNA testing-detectable findings, was 2/101 (2.0%). The DR of cfDNA analysis for genetic aberrations in pregnancies with abnormal ultrasound was 13/35 (37.1%) compared with diagnostic testing. CONCLUSION: In fetuses with sonographic anomalies, the additional DR of combined cfDNA analysis for aneuploidies and 25 SGD was remarkable at 22.9% compared with cfDNA testing for aneuploidies; the overall RR of combined cfDNA analysis was approximately 2.0%. It is essential to provide detailed genetic counseling before using cfDNA analysis in these pregnancies.
引用
- Luong TLA, Nguyen DA, Dao TT, et al. Combined Cell-Free DNA Screening for Aneuploidies and Selected Single-Gene Disorders for Pregnancies With Sonographically Detected Fetal Anomalies: Detection Rate and Residual Risk. Prenat Diagn. 2024. PMID: 39663209. doi:10.1002/pd.6720
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。